Sling`s oral Tepezza rival hits goal in thyroid eye disease, Ph 3
15 Jan 2025 //
PR NEWSWIRE
Sling To Present Ph 2b/3 Linsitinib Results For Thyroid Eye Disease
13 Jan 2025 //
PR NEWSWIRE
Sling Therapeutics Appoints Andrew to its Board of Directors
07 Jan 2025 //
PR NEWSWIRE
Sling Therapeutics to Participate in Upcoming Investor Conferences
08 Nov 2023 //
PR NEWSWIRE
Sling Therapeutics to Participate in the Stifel Virtual I&I Summit
13 Sep 2023 //
PR NEWSWIRE
Sling Presents Data Demonstrating Linsitinib Prevents Thyroid Eye Disease
17 Jun 2023 //
PR NEWSWIRE
Sling Therapeutics Announces Appointment of Jeffrey Kent as CMO
25 Jan 2023 //
PR NEWSWIRE